7 versus 14 days of antibiotic treatment for critically ill patients with bloodstream infection: a pilot randomized clinical trial
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Shorter-duration antibiotic treatment is sufficient for a range of bacterial infections, but has not been adequately studied for bloodstream infections. Our systematic review, survey, and observational study indicated equipoise for a trial of 7 versus 14 days of antibiotic treatment for bloodstream infections; a pilot randomized clinical trial (RCT) was a necessary next step to assess feasibility of a larger trial. METHODS: We conducted an open, pilot RCT of antibiotic treatment duration among critically ill patients with bloodstream infection across 11 intensive care units (ICUs). Antibiotic selection, dosing and route were at the discretion of the treating team; patients were randomized 1:1 to intervention arms consisting of two fixed durations of treatment - 7 versus 14 days. We recruited adults with a positive blood culture yielding pathogenic bacteria identified while in ICU. We excluded patients with severe immunosuppression, foci of infection with an established requirement for prolonged treatment, single cultures with potential contaminants, or cultures yielding Staphylococcus aureus or fungi. The primary feasibility outcomes were recruitment rate and adherence to treatment duration protocol. Secondary outcomes included 90-day, ICU and hospital mortality, relapse of bacteremia, lengths of stay, mechanical ventilation and vasopressor duration, antibiotic-free days, Clostridium difficile, antibiotic adverse events, and secondary infection with antimicrobial-resistant organisms. RESULTS: We successfully achieved our target sample size (n = 115) and average recruitment rate of 1 (interquartile range (IQR) 0.3-1.5) patient/ICU/month. Adherence to treatment duration was achieved in 89/115 (77%) patients. Adherence differed by underlying source of infection: 26/31 (84%) lung; 18/29 (62%) intra-abdominal; 20/26 (77%) urinary tract; 8/9 (89%) vascular-catheter; 4/4 (100%) skin/soft tissue; 2/4 (50%) other; and 11/12 (92%) unknown sources. Patients experienced a median (IQR) 14 (8-17) antibiotic-free days (of the 28 days after blood culture collection). Antimicrobial-related adverse events included hepatitis in 1 (1%) patient, Clostridium difficile infection in 4 (4%), and secondary infection with highly resistant microorganisms in 10 (9%). Ascertainment was complete for all study outcomes in ICU, in hospital and at 90 days. CONCLUSION: It is feasible to conduct a RCT to determine whether 7 versus 14 days of antibiotic treatment is associated with comparable 90-day survival. TRIAL REGISTRATION: ClinicalTrials.gov , identifier: NCT02261506 . Registered on 26 September 2014.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care
Hébert, P. C., Wells, G., Blajchman, M. A., Marshall, J., Martin, C., Pagliarello, G., Tweeddale, M., Schweitzer, I., & Yetisir, E. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400601 · Cited by 5,187 · cited 1×
“Finally, as in other studies that compare two arbitrary and fixed intervention thresholds (such as the TRICC trial of transfusion thresholds) [27], an adequately powered trial will provide a benchmark duration of therapy around which to make individualized treatment decisions.”
BackgroundSelf-citationCONSORT 2010 statement: extension to randomised pilot and feasibility trials
on behalf of the PAFS consensus group, Eldridge, S. M., Chan, C. L., Campbell, M. J., Bond, C. M., Hopewell, S., Thabane, L., & Lancaster, G. A. (2016) · Pilot and Feasibility Studies · doi:10.1186/s40814-016-0105-8 · Cited by 2,843
Self-citationDethlefsen, L., & Relman, D. A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000087107 · Cited by 2,421
Bouadma, L., Luyt, C.-E., Tubach, F., Cracco, C., Alvarez, A., Schwebel, C., Schortgen, F., Lasocki, S., Veber, B., Dehoux, M., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61879-1 · Cited by 1,183
Duration of antibiotic therapy for bacteremia: a systematic review and meta-analysis
Havey, T. C., Fowler, R. A., & Daneman, N. (2011) · Critical Care · doi:10.1186/cc10545 · Cited by 187
Self-citation
Cited by
Yahav, D., Franceschini, E., Koppel, F., Turjeman, A., Babich, T., Bitterman, R., Neuberger, A., Ghanem-Zoubi, N., Santoro, A., Eliakim-Raz, N., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy1054 · Cited by 433
Antibiotic treatment for 7 versus 14 days in patients with bloodstream infections
The BALANCE Investigators (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2404991 · Cited by 158
Arulkumaran, N., Khpal, M., Tam, K., Baheerathan, A., Corredor, C., & Singer, M. (2020) · Critical Care Medicine · doi:10.1097/ccm.0000000000004267 · Cited by 36
Mediavilla, R., Muñoz-Sanjose, A., Rodriguez-Vega, B., Bayon, C., Palao, A., Lahera, G., Sanchez-Castro, P., Roman, E., Cebolla, S., de Diego, A., et al. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2206-4 · Cited by 5
Metadata
- Authors
- on behalf of the Canadian Critical Care Trials Group, Daneman, N., Rishu, A. H., Pinto, R., Aslanian, P., Bagshaw, S. M., Carignan, A., Charbonney, E., Coburn, B., Cook, D. J., Detsky, M. E., Dodek, P., Hall, R., Kumar, A., Lamontagne, F., Lauzier, F., Marshall, J. C., Martin, C. M., McIntyre, L., Muscedere, J., Reynolds, S., Sligl, W., Stelfox, H. T., Wilcox, M. E., & Fowler, R. A.
- Venue
- Trials
- Published
- 2018-02-17
- Volume
- 19
- Issue
- 1
- Pages
- 111-111
- ISSN
- 1745-6215 (ISSN-L)
- OpenAlex
- W2788732937
- Cited by
- 56
- References
- 5
- FWCI
- 5.97
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 7 versus 14 days of antibiotic treatment for critically ill patients with bloodstream infection: a pilot randomized clinical trial. https://app.cochat.ai/papers/10.1186/s13063-018-2474-1
- The paper
- on behalf of the Canadian Critical Care Trials Group, Daneman, N., Rishu, A. H., Pinto, R., Aslanian, P., Bagshaw, S. M., Carignan, A., Charbonney, E., Coburn, B., Cook, D. J., Detsky, M. E., Dodek, P., Hall, R., Kumar, A., Lamontagne, F., Lauzier, F., Marshall, J. C., Martin, C. M., McIntyre, L., . . . Fowler, R. A. (2018). 7 versus 14 days of antibiotic treatment for critically ill patients with bloodstream infection: a pilot randomized clinical trial. Trials. https://doi.org/10.1186/s13063-018-2474-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.